Physician profile
Robert D Hower
NPI 1053407155
$5,358.01
in general payments reported to CMS, 2019-2025
12 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $789 · 2021: $651 · 2022: $965 · 2023: $878 · 2024: $891 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443 · Education: $69.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.06 |
| Education | $69.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,112.42 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $725.82 | 2019-2025 | |
| Boston Scientific Corporation | $343.99 | 2020-2024 | Exalt Model D |
| Ironwood Pharmaceuticals, INC | $297.02 | 2019-2025 | Linzess |
| Celgene Corporation | $294.45 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $223.68 | 2019-2025 | Entyvio |
| Capsovision, INC. | $110.60 | 2023 | Capsocam Plus |
| Pfizer INC. | $109.89 | 2021-2025 | |
| Celltrion USA INC. | $92.55 | 2024-2025 | Zymfentra, Vegzelma |
| Covidien Lp | $24.37 | 2019 | |
| Braintree Laboratories, INC. | $12.33 | 2021 | |
| Ferring Pharmaceuticals INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.